M&A

Mylan and Pfizer roll out tricolor branding for their giant generics combo, Viatris
Mylan and Pfizer roll out tricolor branding for their giant generics combo, Viatris
Fierce Pharma
Mylan
Pfizer
Upjohn
M&A
generics
Viatris
branding
Flag link:
Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale
Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale
Endpoints
Takeda
Shire
M&A
OTC
Flag link:
Sumitomo merges U.S. biotechs to create oncology division
Sumitomo merges U.S. biotechs to create oncology division
Fierce Biotech
Sumitomo Dainippon
Tolero Pharmaceuticals
Boston Biomedical
oncology
M&A
Flag link:
La Jolla to acquire Tetraphase Pharma
La Jolla to acquire Tetraphase Pharma
Seeking Alpha
La Jolla Pharmaceutical
M&A
Tetraphase
Flag link:
After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae
After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae
MedCity News
ArcherDX
M&A
IPOs
cancer
Invitae
Flag link:
Gilead pens $1.5B buyout option deal for Pionyr
Gilead pens $1.5B buyout option deal for Pionyr
Fierce Biotech
Gilead Sciences
Pionyr
M&A
immuno-oncology
Flag link:
After Celgene deal, BMS shoots up pharma market cap rankings
After Celgene deal, BMS shoots up pharma market cap rankings
Pharmaforum
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Amid Allergan buyout, AbbVie dumps unwanted Assembly microbiome pact
Amid Allergan buyout, AbbVie dumps unwanted Assembly microbiome pact
Fierce Biotech
Assembly Biosciences
microbiome
Allergan
AbbVie
M&A
Flag link:
Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns
Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns
Endpoints
AbbVie
Allergan
M&A
FTC
Flag link:
Healthtech Acquisition Worth $16 Million Signals Shift In Clinician-Patient Communication
Healthtech Acquisition Worth $16 Million Signals Shift In Clinician-Patient Communication
Forbes
healthtech
M&A
Induction Healthcare
hospitals
physicians
Zesty
EMRs
patients
Flag link:
Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia
Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia
Xconomy
Novo Nordisk
M&A
Corvidia
kidney disease
Flag link:
Takeda continues post-Shire selloff, inching closer to $10B goal
Takeda continues post-Shire selloff, inching closer to $10B goal
Endpoints
Takeda
Celltrion
M&A
Shire
South Korea
Flag link:
Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition
Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition
Xconomy
Melinta Therapeutics
Tetraphase
M&A
antibiotics
Flag link:
AstraZeneca's Acquisition of Gilead Would Create a COVID-19 Colossus -- but Don't Bet on Seeing It Happen
AstraZeneca's Acquisition of Gilead Would Create a COVID-19 Colossus -- but Don't Bet on Seeing It Happen
Motley Fool
AstraZeneca
Gilead Sciences
M&A
COVID-19
Flag link:
CSL Behring Buys Vitaeris, Picks Up Transplant Rejection Therapeutic
CSL Behring Buys Vitaeris, Picks Up Transplant Rejection Therapeutic
BioSpace
CSL Behring
M&A
Vitaeris
transplant rejection
Flag link:
AstraZeneca reportedly eyed a merger with Gilead. But does 'Gileaz' make sense?
AstraZeneca reportedly eyed a merger with Gilead. But does 'Gileaz' make sense?
Fierce Pharma
M&A
Gilead Sciences
AstraZeneca
Flag link:
UCB buys epilepsy firm Engage Tx in $270m deal
UCB buys epilepsy firm Engage Tx in $270m deal
PM Live
UCB Pharma
epilepsy
M&A
Engage Therapeutics
drug-device combos
Staccato Alprazolam
Flag link:
AstraZeneca Approaches Gilead About Potential Merger
AstraZeneca Approaches Gilead About Potential Merger
Bloomberg
AstraZeneca
Gilead Sciences
M&A
Flag link:
As it happened: A bidding war for an antibiotic maker in a market that has ravaged its peers
As it happened: A bidding war for an antibiotic maker in a market that has ravaged its peers
Endpoints
antibiotics
M&A
Tetraphase
AcelRx
Melinta Therapeutics
La Jolla Pharmaceutical
Flag link:
Bristol's Celgene merger sees it bounce Jounce drug pact
Bristol's Celgene merger sees it bounce Jounce drug pact
Fierce Biotech
Bristol-Myers Squibb
Celgene
Jounce Therapeutics
M&A
immuno-oncology
Flag link:

Pages